"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

Recruiting now · Phase 2/Phase 3

Conditions studied: Ascites Hepatic

In brief

This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.

Key facts

Study ID

NCT07684326

Run by

Beni-Suef University

People needed

52

Starts

2026-07-01

Expected to finish

2027-09-01

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in the study.

You may not qualify if…

• Child Pugh score ≥ 12 or MELD score > 25.
• Previous history of hypoglycemia or has a previous history of DKA.
• Blood pressure less than 90/60 or need dose of midodrine >15 mg/day.
• Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection.
• Pregnant or lactating female patients.
• Hypersensitivity to dapagliflozin.
• eGFR < 30 ml/min/1.73 m2
• Had hepatocellular carcinoma or any malignancy.
• Serum sodium level < 125 mg/dl.
• Portal vein thrombosis.

Where it is running

• Haram Hospital — Giza, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.